Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary


  Malignant Melanoma

  Free Subscription


13.01.2020

1 Am J Dermatopathol
2 Ann Surg Oncol
2 Anticancer Res
1 BMC Cancer
1 Br J Dermatol
1 Curr Opin Oncol
1 Eur J Dermatol
1 J Cell Physiol
2 Melanoma Res
1 Ophthalmology
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Dermatopathol

  1. VYAS NS, Charifa A, Desman GT, Goldberg M, et al
    Observational Study Examining the Diagnostic Practice of Ki67 Staining for Melanocytic Lesions.
    Am J Dermatopathol. 2019;41:488-491.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  2. SONG Y, Straker RJ 3rd, Xu X, Elder DE, et al
    Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma.
    Ann Surg Oncol. 2020 Jan 2. pii: 10.1245/s10434-019-08174.
    PubMed     Text format     Abstract available

  3. MCKINLEY SK, Boland GM
    The Patient Speaks: Importance of Patient Perspectives in Clinical Decision-Making.
    Ann Surg Oncol. 2019;26:2665-2666.
    PubMed     Text format    


    Anticancer Res

  4. REICHRATH J, Lindqvist PG, Pilz S, Marz W, et al
    Sunbeds and Melanoma Risk: Many Open Questions, Not Yet Time to Close the Debate.
    Anticancer Res. 2020;40:501-509.
    PubMed     Text format     Abstract available

  5. BROZYNA AA, Hoffman RM, Slominski AT
    Relevance of Vitamin D in Melanoma Development, Progression and Therapy.
    Anticancer Res. 2020;40:473-489.
    PubMed     Text format     Abstract available


    BMC Cancer

  6. MATTAINI KR, Sullivan MR, Lau AN, Fiske BP, et al
    Increased PHGDH expression promotes aberrant melanin accumulation.
    BMC Cancer. 2019;19:723.
    PubMed     Text format     Abstract available


    Br J Dermatol

  7. CRAIG S, Viros A
    New biomarkers improve stratification of patients with melanoma.
    Br J Dermatol. 2020;182:5-6.
    PubMed     Text format    


    Curr Opin Oncol

  8. TETU P, Baroudjian B, Lebbe C
    Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting.
    Curr Opin Oncol. 2019 Dec 27. doi: 10.1097/CCO.0000000000000614.
    PubMed     Text format     Abstract available


    Eur J Dermatol

  9. NIIJIMA Y, Ishitsuka Y, Inoue S, Maruyama H, et al
    Reconstruction using a vertical "sagging cheek" advancement flap for defects following full-thickness excision of non-melanoma skin cancer in the elderly: a case series.
    Eur J Dermatol. 2019;29:654-656.
    PubMed     Text format    


    J Cell Physiol

  10. DANG N, Meng X, Qin G, An Y, et al
    alpha5-nAChR modulates melanoma growth through the Notch1 signaling pathway.
    J Cell Physiol. 2020 Jan 7. doi: 10.1002/jcp.29435.
    PubMed     Text format     Abstract available


    Melanoma Res

  11. ROZEMAN EA, Prevoo W, Meier MAJ, Sikorska K, et al
    Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM).
    Melanoma Res. 2019 Dec 26. doi: 10.1097/CMR.0000000000000653.
    PubMed     Text format     Abstract available

  12. ATKINSON V, Sandhu S, Hospers G, Long GV, et al
    Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
    Melanoma Res. 2019 Dec 30. doi: 10.1097/CMR.0000000000000654.
    PubMed     Text format     Abstract available


    Ophthalmology

  13. ABRAMSON DH, Francis JH
    Pseudomelanoma (with Cataract) in a Child Caused by Amniocentesis.
    Ophthalmology. 2019;126:590.
    PubMed     Text format    


    PLoS One

  14. FLEM-KARLSEN K, Nyakas M, Farstad IN, McFadden E, et al
    Soluble AXL as a marker of disease progression and survival in melanoma.
    PLoS One. 2020;15:e0227187.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: